BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer Compound


1/14/2013 11:33:46 AM

MONTREAL--(Marketwire - January 15, 2013) - Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB: SBFM), is pleased to announce that it has just filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Advanomics intends to expand this new Adva-27a protection worldwide by filing appropriate international patent applications within the prescribed time limits from this initial filing. Advanomics has recently completed acquisition of the original Adva-27a worldwide patents filed in April 2007 from Institut National des Sciences Appliquees, a government research lab in France. If granted, this new patent filing will extend Adva-27a exclusivity by nearly six years, from April 2027 to January 2033.

Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.

"Having an upgraded patent position is extremely important in the drug business," said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "Coverage of the new molecular aspects of Adva-27a and the approximately six additional years of protection factor significantly into the Company's financial equations," he added.

About Sunshine Biopharma Inc.

Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a which it has licensed on an exclusive basis for the US territory from Advanomics Corporation.

About Advanomics Corporation

Advanomics Corporation is a privately held Canadian company focused on the research and development of treatments for cancer and other human diseases. Advanomics is conducting research and development in the area of Carbon-Difluoride Chemistry to generate novel anticancer compounds and in the area of RNA Technology for deciphering genomic information and rapid identification of disease related molecular targets for therapeutic intervention.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES